DeepMed Research

China National Biotec Group Company Limited

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age

Phase 3

Active, not recruiting

Conditions: Varicella

Interventions: Biological: Investigational live attenuated varicella vaccine (lot 2)
Biological: Investigational live attenuated varicella vaccine (lot 3)
Biological: Investigational live attenuated varicella vaccine (lot 1)

First Posted Date: 2023-05-03

Last Posted Date: 2023-06-18

Lead Sponsor: China National Biotec Group Company Limited

Target Recruit Count: 1200

Registration Number: NCT05839301

Locations: 🇨🇳
Xinyi Center for Disease Control and Prevention, Xuzhou, Jiangsu, China

A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine

Phase 3

Active, not recruiting

Conditions: Varicella

Interventions: Biological: Investigational live attenuated varicella vaccine
Biological: Placebo of live attenuated varicella vaccine

First Posted Date: 2023-01-03

Last Posted Date: 2023-06-18

Lead Sponsor: China National Biotec Group Company Limited

Target Recruit Count: 12440

Registration Number: NCT05669625

Locations: 🇨🇳
Songtao Miao Autonomous County Center for Disease Control and Prevention, Tongren, Guizhou, China
🇨🇳
Yuping Dong Autonomous County Center for Disease Control and Prevention, Tongren, Guizhou, China
🇨🇳
Pei County Center for Disease Control and Prevention, Xuzhou, Jiangsu, China

and more 10 locations

Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population

Phase 4

Conditions: Hemolysis
COVID-19

Interventions: Biological: coadministration
Biological: COVID-19 vaccine
Biological: IIV4+PPV23

First Posted Date: 2022-07-29

Last Posted Date: 2022-08-30

Lead Sponsor: China National Biotec Group Company Limited

Target Recruit Count: 1200

Registration Number: NCT05480436

Locations: 🇨🇳
Xiangya Hospital Central South University, Changsha, China
🇨🇳
Sichuan Center for Disease Control and Prevention, Chengdu, China
🇨🇳
Guizhou Center for Disease Control and Prevention, Guiyang, China

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine

Phase 4

Conditions: COVID-19
Rabies

Interventions: Biological: rabies vaccine
Biological: COVID-19 vaccine
Biological: coadministration

First Posted Date: 2022-07-12

Last Posted Date: 2022-07-29

Lead Sponsor: China National Biotec Group Company Limited

Target Recruit Count: 360

Registration Number: NCT05453487

Locations: 🇨🇳
Guizhou Provincial Center for Disease Control and Prevention, Guiyang, China
🇨🇳
Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China

Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and Above

Phase 3

Active, not recruiting

Conditions: COVID-19

Interventions: Biological: WIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)
Biological: COVID-19 Vaccine (Vero Cell), Inactivated
Biological: BIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)

First Posted Date: 2022-05-19

Last Posted Date: 2023-06-18

Lead Sponsor: China National Biotec Group Company Limited

Target Recruit Count: 1804

Registration Number: NCT05382871

Locations: 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong

Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and Above

Phase 3

Active, not recruiting

Conditions: COVID-19

Interventions: Biological: Omicron COVID-19 Vaccine (Vero Cell), Inactivated
Biological: COVID-19 Vaccine (Vero Cell), Inactivated

First Posted Date: 2022-05-16

Last Posted Date: 2023-06-18

Lead Sponsor: China National Biotec Group Company Limited

Target Recruit Count: 4200

Registration Number: NCT05374954

Locations: 🇨🇳
You County Center for Disease Control and Prevention, Zhuzhou, Hunan, China
🇨🇳
Linli County Center for Disease Control and Prevention, Changde, Hunan, China
🇨🇳
Changning Center for Disease Control and Prevention, Changning, Hunan, China

and more 7 locations

A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and Above

Phase 1

Active, not recruiting

Conditions: COVID-19

Interventions: Biological: Omicron COVID-19 Vaccine (Vero Cell), Inactivated

First Posted Date: 2022-05-09

Last Posted Date: 2023-06-18

Lead Sponsor: China National Biotec Group Company Limited

Target Recruit Count: 280

Registration Number: NCT05365724

Locations: 🇨🇳
Shulan (hangzhou) Hospital, Hangzhou, Zhejiang, China

Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes

Phase 4

Conditions: COVID-19 Pneumonia

Interventions: Biological: Covid-19 vaccine (0-1-4 schedule)
Biological: Covid-19 vaccine (0-1-6 schedule)

First Posted Date: 2021-11-03

Last Posted Date: 2021-11-03

Lead Sponsor: China National Biotec Group Company Limited

Target Recruit Count: 1440

Registration Number: NCT05104437

Locations: 🇨🇳
Nan'an Center for Disease Control and Prevention, Quanzhou, Fujian, China
🇨🇳
Songtao Miao Autonomous County Center for Disease Control and Prevention, Tongren, Guizhou, China
🇨🇳
You County Center for Disease Control and Prevention, Zhuzhou, Hunan, China

Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in People With HIV Infected

Phase 4

Conditions: COVID-19
HIV Infections

Interventions: Biological: Inactivated COVID-19 vaccine

First Posted Date: 2021-11-03

Last Posted Date: 2021-11-03

Lead Sponsor: China National Biotec Group Company Limited

Target Recruit Count: 400

Registration Number: NCT05105295

Locations: 🇨🇳
Zhejiang provincial center for disease control and prevention, Hangzhou, Zhejiang, China

Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes

Phase 4

Conditions: COVID-19 Pneumonia

Interventions: Biological: Covid-19 vaccine (0-1-4 schedule)
Biological: Covid-19 vaccine (0-1-6 schedule)

First Posted Date: 2021-11-03

Last Posted Date: 2021-11-03

Lead Sponsor: China National Biotec Group Company Limited

Target Recruit Count: 1440

Registration Number: NCT05104333

Locations: 🇨🇳
Yong'an Center for Disease Control and Prevention, Sanming, Fujian, China
🇨🇳
Songtao Miao Autonomous County Center for Disease Control and Prevention, Tongren, Guizhou, China
🇨🇳
Linli County Center for Disease Control and Prevention, Changde, Hunan, China

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy